Integumen PLC - Integumen COVID-19 MTA signed with Aptamer Group
AIM share code: SKIN
22 June 2020
("Integumen" or "Company")
Integumen COVID-19 MTA signed with
Collaboration targets wastewater identification of local COVID-19 hotspots
Integumen has signed a Material Transfer Agreement ("MTA") with the
The MTA formalises Integumen's access to
Upon completion of the validation study, Integumen and the
"Integumen's business model is built on collaborating and cooperating with partners such as the
"We are delighted to be working with the Integumen team to transfer developments over the past few weeks by our team in delivering Aptamers that capture the SARS-CoV-2 virus into a real-time wastewater detection solution.
The information communicated in this announcement is inside information for the purposes of Article 7 of EU Regulation 596/2014.
| || |
+44 (0) 7340 055 648
| || |
+44 (0) 113 370 8974
| || || |
+44 (0) 20 3657 0050
Integumen is a scientific research and AI-as-a-Service company focused on production and analysis of bacteria, virus and toxins utilising artificial intelligent data analytics in regulatory technology, from scientifically proving the impact of skincare product claims on skin microbiome for top 10 global cosmetic company clients to remotely detecting water contamination in real-time.
What is an aptamer?
Aptamers are synthetic molecules specifically created to bind to another (usually larger) molecule with a very high attraction to a given target. These short nucleic acid sequences (DNA or RNA), wrap around all or part of their target (in the case of small molecules) or fit snugly into clefts and gaps within the surface of much larger target molecules (for proteins, cells, tissues etc). This ability to fold into or around the complex surfaces of a target, means that it is possible to select aptamers against almost any given target, with precision.
This information is provided by RNS, the news service of the
Quick facts: Integumen
Market Cap: £30.21 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE